Literature DB >> 9463788

Practical considerations and guidelines for the management of community-acquired pneumonia.

R G Finch1, M A Woodhead.   

Abstract

Community-acquired pneumonia (CAP) is a common condition which has a significant mortality. The management of a patient with CAP is centred around assessment and correction of gas exchange and fluid balance together with administration of appropriate antibiotics. Up to 10 different pathogens regularly cause CAP, of which Streptococcus pneumoniae is the most important. These different pathogens cannot be distinguished by clinical features or simple laboratory tests. Microbiological tests are slow and insensitive, so empirical therapy is necessary, at least initially. Accurate assessment of illness severity is the most important factor determining initial management, since this assists the decision of whether to admit the patient to hospital in addition to guiding antibiotic choice and route of administration. Two different approaches to severity assessment are outlined. Our antibiotic recommendation for empirical therapy for the patient managed at home and the previously fit patient admitted to hospital is amoxicillin. Amoxicillin/clavulanate plus a macrolide is our choice for the severely ill previously fit patient and a third-generation cephalosporin plus a macrolide is recommended for the severely ill patient with comorbidity. Alternative pathogens and specific treatment regimens are also described. There may be several causes of treatment failure, and in patients who fail to respond to therapy, it is essential to review all the initial clinical and laboratory information, which if necessary must be repeated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9463788     DOI: 10.2165/00003495-199855010-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   11.431


  56 in total

1.  Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital.

Authors:  R Bohte; R van Furth; P J van den Broek
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

2.  Impact of management guidelines on the outcome of severe community acquired pneumonia.

Authors:  N A Hirani; J T Macfarlane
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

Review 3.  Community-acquired pneumonia.

Authors:  J G Bartlett; L M Mundy
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

4.  Sparfloxacin empirical therapy in community-acquired pneumonia. Results of a meta-analysis of 2 comparative studies.

Authors:  G G Grassi; I Brumpt
Journal:  Drugs       Date:  1995       Impact factor: 9.546

5.  The importance of Coxiella burnetii as a cause of pneumonia in Nova Scotia.

Authors:  T J Marrie; E V Haldane; R S Faulkner; C Kwan; B Grant; F Cook
Journal:  Can J Public Health       Date:  1985 Jul-Aug

6.  Severe community-acquired pneumonia. Etiology, prognosis, and treatment.

Authors:  J Pachon; M D Prados; F Capote; J A Cuello; J Garnacho; A Verano
Journal:  Am Rev Respir Dis       Date:  1990-08

7.  Etiology of community-acquired pneumonia in patients requiring hospitalization.

Authors:  E Berntsson; J Blomberg; T Lagergård; B Trollfors
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

8.  Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow-up.

Authors:  H Holmberg; P Kragsbjerg
Journal:  Scand J Infect Dis       Date:  1993

9.  Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study.

Authors:  J Almirall; I Morató; F Riera; A Verdaguer; R Priu; P Coll; J Vidal; L Murgui; F Valls; F Catalan
Journal:  Eur Respir J       Date:  1993-01       Impact factor: 16.671

10.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

Authors:  M J Fine; M A Smith; C A Carson; S S Mutha; S S Sankey; L A Weissfeld; W N Kapoor
Journal:  JAMA       Date:  1996-01-10       Impact factor: 56.272

View more
  12 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.

Authors:  Jun-Ichi Kadota; Yuji Ishimatsu; Tetsuji Iwashita; Yuichi Matsubara; Kazunori Tomono; Masao Tateno; Roza Ishihara; Claudette Muller-Serieys; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department.

Authors:  S G Campbell; T J Marrie; R Anstey; S Ackroyd-Stolarz; G Dickinson
Journal:  Emerg Med J       Date:  2003-11       Impact factor: 2.740

Review 4.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Authors:  J A Balfour; H M Lamb
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

6.  Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Authors:  C Muller-Serieys; P Soler; C Cantalloube; F Lemaitre; H P Gia; F Brunner; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Infectious background of febrile advanced lung cancer patients who received chemotherapy.

Authors:  Katsuhiro Masago; Akiko Fukuhara; Yutaka Ito; Yukimasa Hatachi; Kaoru Irisa; Yuichi Sakamori; Yosuke Togashi; Shiro Fujita; Young Hak Kim; Tadashi Mio; Michiaki Mishima
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

8.  Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures?

Authors:  Samuel George Campbell; R Andrew McIvor; Vincent Joanis; David Graydon Urquhart
Journal:  World J Emerg Med       Date:  2011

9.  Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice : evidence from a post-marketing surveillance study of 1467 patients.

Authors:  H Koch; H Landen; K Stauch
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

10.  Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus.

Authors:  Véronique Boussaud; Antoine Parrot; Charles Mayaud; Marie Wislez; Martine Antoine; Clément Picard; Françoise Delisle; Jérome Etienne; Jacques Cadranel
Journal:  Intensive Care Med       Date:  2003-08-02       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.